Retarding progression of chronic renal disease: the neglected issue of residual proteinuria
- PMID: 12753315
- DOI: 10.1046/j.1523-1755.2003.00033.x
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria
Abstract
Background: Findings that early changes in proteinuria independently predict long-term glomular filtration rate (GFR) decline (Delta GFR) would highlight proteinuria as a major determinant of progression in chronic renal disease.
Methods: We investigated whether percent changes (3 months vs. baseline) in proteinuria (adjusted for concomitant changes in GFR) and residual proteinuria at 3 months, predicted Delta GFR [over a median (IQ range) follow up of 31.3 (24.5 to 50.3) months] in 273 patients with proteinuric chronic nephropathies enrolled in the Ramipril Efficacy In Nephropathy (REIN) study.
Results: Short-term changes and residual proteinuria (r = -0.23, P = 0.0001 for both) significantly correlated with Delta GFR and, at multivariate analyses, independently predicted Delta GFR (beta = -0.23, P = 0.0002; beta = -0.21, P = 0.0004, respectively). For comparable levels of residual proteinuria, patients with greater short-term reduction had slower Delta GFR (-0.28 +/- 0.04 mL/min/1.73 m2/ vs. -0.53 +/- 0.07 mL/min/1.73 m2/month, P = 0.04). On ramipril and conventional treatment, specular short-term changes in proteinuria (-18.2 +/- 3.5% vs. 24.2 +/- 6.7%, P < 0.0001, respectively) were associated with significantly different Delta GFRs. However, similar changes in proteinuria resulted in a difference in Delta GFR (ramipril, 0.39 +/- 0.07 mL/min/1.73 m2/month; conventional therapy, 0.74 +/- 0.11 mL/min/1.73 m2/month; P < 0.01) that was sevenfold higher (0.35 vs. 0.05 mL/min/1.73 m2/month) in patients with basal proteinuria > or =3 g/24 hours as compared to those with basal proteinuria 1 to 3 g/24 hours (ramipril, 0.25 +/- 0.06 mL/min/1.73 m2/month; conventional therapy, 0.30 +/- 0.07 mL/min/1.73 m2/month; P = NS).
Conclusion: Regardless of blood pressure control and treatment randomization, short-term changes in proteinuria and residual proteinuria reliably predict long-term disease progression. Reducing proteinuria is renoprotective, particularly in nephrotic patients. As for arterial hypertension, proteinuria should be a specific target for renoprotective treatment.
Similar articles
-
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).Kidney Int. 1998 May;53(5):1209-16. doi: 10.1046/j.1523-1755.1998.00874.x. Kidney Int. 1998. PMID: 9573535 Clinical Trial.
-
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).Kidney Int Suppl. 1997 Dec;63:S54-7. Kidney Int Suppl. 1997. PMID: 9407422 Clinical Trial.
-
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).Lancet. 1997 Jun 28;349(9069):1857-63. Lancet. 1997. PMID: 9217756 Clinical Trial.
-
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.J Nephrol. 2002 Jul-Aug;15(4):428-30. J Nephrol. 2002. PMID: 12243375 Review.
-
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S58-63. doi: 10.1681/asn.2004110968. J Am Soc Nephrol. 2005. PMID: 15938036 Review.
Cited by
-
The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease.Rambam Maimonides Med J. 2015 Jul 30;6(3):e0029. doi: 10.5041/RMMJ.10214. Rambam Maimonides Med J. 2015. PMID: 26241225 Free PMC article.
-
Endothelin-1 and the kidney--beyond BP.Br J Pharmacol. 2012 Oct;167(4):720-31. doi: 10.1111/j.1476-5381.2012.02070.x. Br J Pharmacol. 2012. PMID: 22670597 Free PMC article. Review.
-
Novel drugs and intervention strategies for the treatment of chronic kidney disease.Br J Clin Pharmacol. 2013 Oct;76(4):536-50. doi: 10.1111/bcp.12195. Br J Clin Pharmacol. 2013. PMID: 23802504 Free PMC article. Review.
-
Predictors of progression in hypertensive renal disease in children.J Clin Hypertens (Greenwich). 2004 Apr;6(4):186-91. doi: 10.1111/j.1524-6175.2004.02617.x. J Clin Hypertens (Greenwich). 2004. PMID: 15073472 Free PMC article.
-
Compelling drug indications in diabetic and nondiabetic nephropathy.Curr Hypertens Rep. 2004 Aug;6(4):293-9. doi: 10.1007/s11906-004-0024-6. Curr Hypertens Rep. 2004. PMID: 15257864 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
